title: Differential and tumor-specific expression of CD160 in B-cell malignancies.
abstract: CD160 is a human natural killer (NK)-cell-activating receptor that is also expressed on T-cell subsets. In the present study, we examined 811 consecutive cases of B-cell lymphoproliferative disorders (B-LPDs), and demonstrated CD160 expression in 98% (590 of 600) of chronic lymphocytic leukemia (CLL) cases, 100% (32 of 32) of hairy cell leukemia (HCL) cases, 15% (5 of 34) of mantle cell lymphoma (MCL) in the leukemic phase, and 16% (23 of 145) of other B-LPD cases. CD160 transcript and protein were absent in the normal B-cell hierarchy, from stem cells, B-cell precursors, maturing B cells in the germinal center, and circulating B cells, including CD5(+)CD19(+) B1 cells in umbilical cord. CD160 positivity was significantly higher in CLL and HCL in terms of percentage (65.9% and 67.8%, respectively, P < .0001) and median fluorescence intensity (552 and 857, respectively, P < .0001) compared with all other B-LPD cases. Lymph node CLL samples were also CD160(+). Using the disease-specific expression of CD5, CD23, and CD160, a score of 3 characterized CLL (diagnostic odds ratio, 1430); a score of 0 excluded CLL, MCL, and HCL; and the CD23/CD5 ratio differentiated CLL from leukemic CD23(+) MCL. In the B-cell lineage, CD160 is a tumor-specific antigen known to mediate cellular activation signals in CLL, and is a novel target for therapeutic manipulation and monitoring of minimal residual disease.
authors.affiliation: Division of Haemato-Oncology and Immunophenotyping Section, Department of Haematology, Barts and The London National Health Service (NHS) Trust, London, UK.
authors.forename: Timothy W
authors.initials: TW
authors.lastname: Farren
authors.forename: Jerome
authors.initials: J
authors.lastname: Giustiniani
authors.forename: Feng-Ting
authors.initials: FT
authors.lastname: Liu
authors.forename: Dimitris A
authors.initials: DA
authors.lastname: Tsitsikas
authors.forename: Marion G
authors.initials: MG
authors.lastname: Macey
authors.forename: James D
authors.initials: JD
authors.lastname: Cavenagh
authors.forename: Heather E
authors.initials: HE
authors.lastname: Oakervee
authors.forename: David
authors.initials: D
authors.lastname: Taussig
authors.forename: Adrian C
authors.initials: AC
authors.lastname: Newland
authors.forename: Maria
authors.initials: M
authors.lastname: Calaminici
authors.forename: Armand
authors.initials: A
authors.lastname: Bensussan
authors.forename: Michael
authors.initials: M
authors.lastname: Jenner
authors.forename: John G
authors.initials: JG
authors.lastname: Gribben
authors.forename: Samir G
authors.initials: SG
authors.lastname: Agrawal
mesh_terms: D015703:Antigens, CD / Q000235:genetics / Q000378:metabolism*; D001402:B-Lymphocytes / Q000276:immunology*; D001483:Base Sequence; D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism; D015331:Cohort Studies; D017931:DNA Primers / Q000235:genetics; D004273:DNA, Neoplasm / Q000235:genetics; D058851:GPI-Linked Proteins / Q000235:genetics / Q000378:metabolism; D015870:Gene Expression; D006801:Humans; D007150:Immunohistochemistry; D007943:Leukemia, Hairy Cell / Q000235:genetics / Q000276:immunology; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000235:genetics / Q000276:immunology; D008218:Lymphocytosis / Q000235:genetics / Q000276:immunology; D020522:Lymphoma, Mantle-Cell / Q000235:genetics / Q000276:immunology; D008232:Lymphoproliferative Disorders / Q000175:diagnosis / Q000235:genetics / Q000276:immunology*; D011971:Receptors, Immunologic / Q000235:genetics / Q000378:metabolism*
chemical_list: D015703:Antigens, CD; D014408:Biomarkers, Tumor; C114505:CD160 protein, human; D017931:DNA Primers; D004273:DNA, Neoplasm; D058851:GPI-Linked Proteins; D011971:Receptors, Immunologic